An2 Therapeutics Inc (ANTX) Stock Price, Quote & News

Company Profile

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chag...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 331 9090

Website: www.an2therapeutics.com

Address:

1300 El Camino Real, Suite 100, Menlo Park, United States

mockbae63 May. 18 at 11:16 PM

$ANTX Do not short this one tomorrow. Could be an insane rally.

0 · Reply

BPharmCatalyst May. 15 at 3:23 PM

Biotech volatility is heating up into quarter end 🚨 These 3 upcoming Phase 1 catalysts could have major valuation implications for the companies behind them: $TVRD — STAT3 inhibitor safety + PK data $ANTX — Chagas disease curative potential $CAPR — StealthX exosome vaccine platform data Watch the full Weekly Watchlist Speed Run👇 https://www.youtube.com/@BioPharmCatalyst/shorts #Biotech #Stocks #Investing #ClinicalTrials #FDA #Shorts

0 · Reply

SmartMoneyTradez Apr. 28 at 6:11 PM

$ANTX $QNTM slow grind up

1 · Reply

Mellowfellow Apr. 27 at 9:09 PM

$ANTX Another 10% moving up nicely!

0 · Reply

Mellowfellow Apr. 23 at 10:12 PM

$ANTX This is quietly moving up but needs more volume.

0 · Reply

Doozio Apr. 19 at 5:40 PM

$ANTX well all da 🐑 been SPOT. Let’s bang bro. Up da Roger n next pivot is ONTO 🐒🍌🧠⏰♾️

0 · Reply

Oscarthesuperstar1 Apr. 19 at 11:21 AM

$ANTX Reversal. NFA

0 · Reply

Slingshot Apr. 18 at 5:27 AM

$ANTX 🔥

0 · Reply

outlawinvestor1 Apr. 10 at 8:46 PM

$ANTX started a position at my target $3/sh. 🤞🤞

0 · Reply

focafoca99 Apr. 10 at 6:01 PM

$ANTX entered into an open-market sale agreement with Jefferies that allows for up to $80 million of at-the-market common-stock sales.

0 · Reply

AN2 Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum

2026-05-14T10:33:59.000Z - 5 days ago

AN2 Therapeutics upgraded to Outperform from Market Perform at Leerink

2026-05-11T21:38:16.000Z - 8 days ago

AN2 Therapeutics reports Q1 EPS (29c), one estimate (23c)

May 11, 2026, 4:01 PM EDT - 8 days ago

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

May 11, 2026, 4:00 PM EDT - 8 days ago

AN2 Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 8 days ago

AN2 Therapeutics Quarterly report: Q1 2026

May 7, 2026, 4:01 PM EDT - 12 days ago

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

Apr 22, 2026, 8:00 AM EDT - 27 days ago

AN2 Therapeutics Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 27 days ago

AN2 Therapeutics Proxy statement: Proxy filing

2026-04-09T21:25:44.000Z - 5 weeks ago

AN2 Therapeutics files $300M mixed securities shelf

Apr 9, 2026, 8:00 AM EDT - 5 weeks ago

AN2 Therapeutics Registration statement: Registration filing

2026-03-31T11:05:31.000Z - 7 weeks ago

AN2 Therapeutics announces initiation of Phase 2 trial of epetraborole

Mar 31, 2026, 7:00 AM EDT - 7 weeks ago

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

2026-03-17T20:05:56.000Z - 2 months ago

AN2 Therapeutics reports Q4 EPS (29c) vs (25c) last year

Mar 17, 2026, 4:00 PM EDT - 2 months ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

Mar 17, 2026, 4:00 PM EDT - 2 months ago

AN2 Therapeutics Annual report: Q4 2025

Mar 17, 2026, 4:00 PM EDT - 2 months ago

AN2 Therapeutics Earnings release: Q4 2025

Mar 17, 2026, 8:00 AM EDT - 2 months ago

AN2 Therapeutics Slides: Investor presentation

Mar 10, 2026, 3:40 PM EDT - 2 months ago

AN2 Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 7:00 AM EDT - 2 months ago

AN2 Therapeutics Announces $40 Million Private Placement Financing

Mar 4, 2026, 9:30 AM EST - 2 months ago

AN2 Therapeutics Transcript: Status update

Mar 4, 2026, 9:30 AM EST - 2 months ago

AN2 Therapeutics Press release: Status update

Mar 4, 2026, 9:30 AM EST - 2 months ago

AN2 Therapeutics Slides: Status update

2026-03-03T21:08:15.000Z - 2 months ago

AN2 Therapeutics to advance oral Epetraborole into Phase 2 study

Mar 3, 2026, 4:00 PM EST - 2 months ago

AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

Feb 17, 2026, 7:00 AM EST - 3 months ago

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

2026-01-12T12:18:28.000Z - 4 months ago

AN2 Therapeutics announces FDA clearance of OSHU IND application

Jan 12, 2026, 7:00 AM EST - 4 months ago

AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease

Dec 3, 2025, 10:50 AM EST - 5 months ago

AN2 Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

2025-11-12T21:05:35.000Z - 6 months ago

AN2 Therapeutics reports Q3 EPS (31c), two estimates (22c)

Nov 12, 2025, 4:01 PM EST - 6 months ago

AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

Nov 12, 2025, 4:00 PM EST - 6 months ago

AN2 Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 6 months ago

AN2 Therapeutics Quarterly report: Q3 2025

2025-11-10T12:20:58.000Z - 6 months ago

AN2 Therapeutics announces tuberculosis collaboration agreement with GSK

GSK

Nov 10, 2025, 7:00 AM EST - 6 months ago

AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

Nov 6, 2025, 5:03 PM EST - 6 months ago

AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference

2025-08-12T20:06:25.000Z - 10 months ago

AN2 Therapeutics reports Q2 EPS (21c) vs. (48c) last year

Aug 12, 2025, 4:01 PM EDT - 10 months ago

AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights

2025-08-12T11:11:29.000Z - 10 months ago

AN2 Therapeutics completes dosing in cohort in AN2-502998 trial

Aug 12, 2025, 7:00 AM EDT - 10 months ago

AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

Aug 12, 2025, 7:00 AM EDT - 10 months ago

AN2 Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 10 months ago

AN2 Therapeutics Quarterly report: Q2 2025

2025-07-23T11:30:57.000Z - 10 months ago

AN2 Therapeutics, DNDi collaborate on development of AN2-502998

Jul 23, 2025, 7:00 AM EDT - 10 months ago

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

2025-06-30T11:24:51.000Z - 11 months ago

AN2 Therapeutics completes 200-patient observational study in acute melioidosis

Jun 30, 2025, 7:00 AM EDT - 11 months ago

AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole

May 29, 2025, 7:00 AM EDT - 1 year ago

AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference

2025-05-13T20:07:01.000Z - 1 year ago

AN2 Therapeutics reports Q1 EPS (35c) vs. (56c) last year

May 13, 2025, 4:01 PM EDT - 1 year ago

AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights

May 13, 2025, 12:00 AM EDT - 1 year ago

AN2 Therapeutics Earnings release: Q1 2025

May 13, 2025, 12:00 AM EDT - 1 year ago

AN2 Therapeutics Quarterly report: Q1 2025

May 7, 2025, 9:00 AM EDT - 1 year ago

AN2 Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

2025-05-05T09:21:58.000Z - 1 year ago

AN2 Therapeutics price target lowered to $2 from $5 at Citizens JMP

2025-05-01T20:22:51.000Z - 1 year ago

AN2 Therapeutics reports data fro previously terminated EBO-301 Study

May 1, 2025, 4:00 PM EDT - 1 year ago

AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline

Apr 30, 2025, 7:00 AM EDT - 1 year ago

AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference

Apr 10, 2025, 8:00 AM EDT - 1 year ago

AN2 Therapeutics Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

AN2 Therapeutics Proxy statement: Proxy Filing

2025-03-25T20:06:30.000Z - 1 year ago

AN2 Therapeutics reports Q4 EPS (25c) vs (57c) last year

Mar 25, 2025, 4:00 PM EDT - 1 year ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

Mar 25, 2025, 8:00 AM EDT - 1 year ago

AN2 Therapeutics Annual report: Q4 2024

Mar 25, 2025, 8:00 AM EDT - 1 year ago

AN2 Therapeutics Earnings release: Q4 2024

Mar 12, 2025, 2:20 PM EDT - 1 year ago

AN2 Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 3, 2025, 4:00 PM EST - 1 year ago

AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

Mar 3, 2025, 2:30 PM EST - 1 year ago

AN2 Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

2025-02-24T12:15:12.000Z - 1 year ago

AN2 Therapeutics submits amended EBO-301 trial statistical analysis plan to FDA

$AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease$

Feb 24, 2025, 7:00 AM EST - 1 year ago

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

Feb 20, 2025, 7:00 AM EST - 1 year ago

AN2 Therapeutics to Participate at Upcoming Investor Conferences

Feb 12, 2025, 3:20 PM EST - 1 year ago

AN2 Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Jan 29, 2025, 4:00 PM EST - 1 year ago

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nov 13, 2024, 4:00 PM EST - 1 year ago

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

Nov 13, 2024, 7:00 AM EST - 1 year ago

AN2 Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

AN2 Therapeutics Earnings release: Q3 2024

Oct 17, 2024, 7:00 AM EDT - 1 year ago

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

Aug 28, 2024, 4:00 PM EDT - 1 year ago

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 7:00 AM EDT - 1 year ago

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

Aug 13, 2024, 4:01 PM EDT - 1 year ago

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Aug 13, 2024, 7:00 AM EDT - 1 year ago

AN2 Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 1 year ago

AN2 Therapeutics Earnings release: Q2 2024

$AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease$

Aug 8, 2024, 4:30 PM EDT - 1 year ago

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

May 14, 2024, 4:01 PM EDT - 2 years ago

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights

May 14, 2024, 8:00 AM EDT - 2 years ago

AN2 Therapeutics Quarterly report: Q1 2024

May 14, 2024, 8:00 AM EDT - 2 years ago

AN2 Therapeutics Earnings release: Q1 2024

Apr 26, 2024, 8:00 AM EDT - 2 years ago

AN2 Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

AN2 Therapeutics Proxy statement: Proxy Filing

Apr 5, 2024, 8:00 AM EDT - 2 years ago

AN2 Therapeutics Proxy statement: Proxy Filing

Mar 28, 2024, 4:10 PM EDT - 2 years ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Mar 28, 2024, 8:00 AM EDT - 2 years ago

AN2 Therapeutics Annual report: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

AN2 Therapeutics Earnings release: Q4 2023

Feb 12, 2024, 6:56 AM EST - 2 years ago

AN2 Therapeutics to pause lung disease study enrollment

$AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease$

Feb 12, 2024, 6:45 AM EST - 2 years ago

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

Jan 30, 2024, 4:10 PM EST - 2 years ago

AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference

Nov 9, 2023, 4:05 PM EST - 2 years ago

AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights

Nov 9, 2023, 7:00 AM EST - 2 years ago

AN2 Therapeutics Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

AN2 Therapeutics Earnings release: Q3 2023

Nov 6, 2023, 7:00 AM EST - 2 years ago

AN2 Therapeutics to Present at Upcoming Investor Conferences

Oct 18, 2023, 7:00 AM EDT - 2 years ago

AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease

Oct 11, 2023, 12:01 AM EDT - 2 years ago

AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

Sep 26, 2023, 7:00 AM EDT - 2 years ago

AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria

$AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease$

Sep 13, 2023, 7:00 AM EDT - 2 years ago

AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease

Aug 15, 2023, 10:42 PM EDT - 3 years ago

AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock

Aug 10, 2023, 4:10 PM EDT - 3 years ago

AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

Aug 10, 2023, 7:00 AM EDT - 3 years ago

AN2 Therapeutics Quarterly report: Q2 2023

Aug 10, 2023, 7:00 AM EDT - 3 years ago

AN2 Therapeutics Earnings release: Q2 2023

May 25, 2023, 4:10 PM EDT - 3 years ago

AN2 Therapeutics to Present at Jefferies Healthcare Conference

mockbae63 May. 18 at 11:16 PM

$ANTX Do not short this one tomorrow. Could be an insane rally.

0 · Reply

BPharmCatalyst May. 15 at 3:23 PM

0 · Reply

SmartMoneyTradez Apr. 28 at 6:11 PM

$ANTX $QNTM slow grind up

1 · Reply

Mellowfellow Apr. 27 at 9:09 PM

$ANTX Another 10% moving up nicely!

0 · Reply

Mellowfellow Apr. 23 at 10:12 PM

$ANTX This is quietly moving up but needs more volume.

0 · Reply

Doozio Apr. 19 at 5:40 PM

$ANTX well all da 🐑 been SPOT. Let’s bang bro. Up da Roger n next pivot is ONTO 🐒🍌🧠⏰♾️

0 · Reply

Oscarthesuperstar1 Apr. 19 at 11:21 AM

$ANTX Reversal. NFA

0 · Reply

Slingshot Apr. 18 at 5:27 AM

$ANTX 🔥

0 · Reply

outlawinvestor1 Apr. 10 at 8:46 PM

$ANTX started a position at my target $3/sh. 🤞🤞

0 · Reply

focafoca99 Apr. 10 at 6:01 PM

$ANTX entered into an open-market sale agreement with Jefferies that allows for up to $80 million of at-the-market common-stock sales.

0 · Reply

Biotech_Pharma_Investor Apr. 10 at 3:55 PM

$ANTX Trading near cash with a runway into 2029 and multiple shota on goal within runway + an underestimated preclinical oncology pipeline with best-in-class potential.

0 · Reply

OfficialStocktwitsUser Apr. 2 at 4:18 AM

$ANTX RSI: 16.27, MACD: 0.3390 Vol: 0.96, MA20: 4.09, MA50: 2.30 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

outlawinvestor1 Mar. 31 at 1:06 PM

$ANTX getting closer to my buy price.

0 · Reply

DARKP00L Mar. 31 at 11:25 AM

$ANTX 07:07 on Mar. 31 2026 AN2 Therapeutics Initiates Phase 2 Trial Of leucyl-tRNA Synthetase (LeuRS) Mycobacterium Abscessus, With Topline Data Planned For Late 2027 #tradeideas

0 · Reply

MikiTrader Mar. 30 at 6:03 AM

$ANTX It looks like someone stepped in to try to push it up again… and I think I know who it might be. But the market doesn't seem to have much expectation, at least not until June. In my view, it probably needs to drop another 30% or so. Even if it does go up, it's driven by uncertainty, so I don't think it will go very far.

0 · Reply

MrBruceWayne Mar. 29 at 2:03 PM

🚨💎 BUY ALERT $ANTX

1 · Reply

jcooptechit Mar. 24 at 1:57 PM

$BSEM Keep a close eye on BioStem! Major potential success story in the making. $ACXP $ANTX $CTMX $TRAW

0 · Reply

No_Face_character Mar. 19 at 6:19 PM

$ANTX .500 fib retrace is 3.99, so it's there. lower Bollinger is 3.59. any bounce should be today/tomorrow

0 · Reply

outlawinvestor1 Mar. 19 at 3:52 PM

$ANTX i remain bullish on potential here, but as suspected the sp is undergoing a correction. fully diluted cash per share is $2.41 and recent financing was done at $2.85/sh. i will start building a position closer to $3.

1 · Reply

mockbae63 Mar. 19 at 2:48 PM

$ANTX Called it weeks ago. Just have to stay patient on the shorts. Good job to everyone who made money.

1 · Reply

stockwitsuser2449 Mar. 18 at 8:25 PM

$CTMX $ANTX

0 · Reply

stockwitsuser2449 Mar. 18 at 6:57 PM

$CTMX so this and $ANTX the race is on...who will finish lowest today, this week, this month! guesses anyone?

0 · Reply

Market Cap	161.35M
Revenue (ttm)	0.00
Net Income (ttm)	-35.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	83,600
Avg Vol	457,022
Day's Range	N/A - N/A
Shares Out	36.02M
Stochastic %K	58%
Beta	-0.95
Analysts	Strong Sell
Price Target	$9.00